ADC Therapeutics
ADCT
118 hedge funds and large institutions have $313M invested in ADC Therapeutics in 2026 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 53 increasing their positions, 28 reducing their positions, and 14 closing their positions.
24,967% more call options, than puts
Call options by funds: $752K | Put options by funds: $3K
89% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 28
36% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 14
7% more capital invested
Capital invested by funds: $293M → $313M (+$20.1M)
3% more funds holding
Funds holding: 115 → 118 (+3)
1.16% less ownership
Funds ownership: 66.89% → 65.74% (-1.2%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| 1 |
Millennium Management
New York
|
+$11M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$9.22M |
| 3 |
BlackRock
New York
|
+$3.25M |
| 4 |
Two Sigma Investments
New York
|
+$2.16M |
| 5 |
Renaissance Technologies
New York
|
+$1.18M |
Top Sellers
| 1 |
O
OrbiMed
New York
|
-$17.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.44M |
| 3 |
SC
Stempoint Capital
New York
|
-$1.77M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$774K |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
-$699K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EGM
126
Engineers Gate Manager
New York
| – | -$42.6K | -12,071 | Closed |
|
|
AB
127
Amalgamated Bank
New York
| – | -$10K | -2,710 | Closed |
|
128
Simplex Trading
Chicago,
Illinois
| – | -$10.6K | -2,687 | Closed |
|
129
Los Angeles Capital Management
Los Angeles,
California
| – | -$7.99K | -1,725 | Closed |
|
|
SS
130
SBI Securities
Tokyo,
Japan
| – | -$784 | -222 | Closed |
|
|
FFA
131
Farther Finance Advisors
San Francisco,
California
| – | -$201 | -57 | Closed |
|
|
AAP
132
Arax Advisory Partners
Denver,
Colorado
| – | -$60 | -17 | Closed |
|
ADCT Hedge Fund Activity: Q1 2026 in Review
118 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in ADC Therapeutics (ADCT) for Q1 2026, worth a combined $313M — up 6.8% from $293M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ADCT positions and 14 closed out — a net gain of 5 holders — while 53 added to existing stakes and 28 trimmed.
The largest buyer was Millennium Management, adding an estimated $11M. The largest seller was OrbiMed, cutting an estimated $17.8M.
- 118 institutional investors held ADC Therapeutics (ADCT) as of Q1 2026, up from 115 in Q4 2025.
- Funds reported $313M of ADC Therapeutics stock for Q1 2026, up 6.8% quarter-over-quarter.
- 19 funds opened new ADC Therapeutics positions in Q1 2026 and 14 closed out, a net change of +5 holders.
- The largest ADC Therapeutics buyer in Q1 2026 was Millennium Management, an estimated $11M added.
- The largest ADC Therapeutics seller in Q1 2026 was OrbiMed, an estimated $17.8M sold.
Based on aggregated 13F filings for Q1 2026.